Overview
Garonit Pharmaceutical produces Active Pharmaceutical Ingredients, especially Chlorhexidine Gluconate, for global pharmaceutical customers. It uses a vertically integrated model from intermediates to finished dosage forms with cGMP/WHO-GMP facilities in the US and India and distribution warehouses in Europe. It plans a 200,000-square-foot New Windsor facility to become the world’s largest Chlorhexidine Gluconate producer, supported by New York state grants and including an R&D center for FDA-regulated products. With certifications from US FDA, EDQM, and PMDA, it competes on scale, end-to-end manufacturing, and global reach, aiming to supply large-scale, compliant Chlorhexidine Gluconate worldwide while expanding U.S. operations and developing FDA-regulated formulations.
Work here?Claim your company
Simplify's take
What believers are saying
- New York backed Garonit’s $46.1 million New Windsor project with $3.8 million in support.
- The facility targets January 2027 startup and 100 to 150 construction jobs.
- Garonit’s 2026-10-29 site says Flanders headquarters now spans 320,000-plus square feet.
What critics are saying
- On 2026-05-05, New Windsor still needed FAA, NYSDEC, and health-department coordination.
- California’s 2025-09-25 Prop 65 notice named Garonit Pharmaceutical and Garonit Pharmaceutical Distribution.
- A contamination or FDA enforcement action could shut chlorhexidine supply and cripple the business.
What makes Garonit Pharmaceutical unique
- Garonit controls APIs, finished dosage, and global distribution across New Jersey, Mumbai, and Europe.
- Its chlorhexidine gluconate specialization anchors a defensible antiseptic niche with FDA, EDQM, and PMDA registrations.
- The 2026 New Windsor plant targets world-scale chlorhexidine output and an integrated R&D center.
Help us improve and share your feedback! Did you find this helpful?